NCT06714383 Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
| NCT ID | NCT06714383 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Peking University People's Hospital |
| Condition | Osteosarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-11-13 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2024-11-13 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent signed; 2. Classic osteosarcoma confirmed by histopathology (high grade); 3. Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria; 4. Planned to receive neoadjuvant chemotherapy; 5. Measurable disease on CT by RECIST 1.1. 6. No antitumor system therapy received; 7. ECOG 0-1 8. Adequate organ function. 9. Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication. Exclusion Criteria: 1. History of malignancies of other type; 2. Allergic to study agent; 3. History of psychotropic substance abuse, alcohol or drug use; 4. The researchers considered inappropriate to join the study of any cause.
Frequently Asked Questions
Who can join the NCT06714383 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 70 Years, studying Osteosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06714383 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06714383 currently recruiting?
Yes, NCT06714383 is actively recruiting participants. Visit ClinicalTrials.gov or contact Peking University People's Hospital to inquire about joining.
Where is the NCT06714383 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06714383 clinical trial?
NCT06714383 is sponsored by Peking University People's Hospital. The trial plans to enroll 50 participants.